News
When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Zacks Investment Research on MSN1d
Septerna Stock Surges on Oral Obesity Drug Deal With Novo NordiskShares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback